Hologic, Inc. (HOLX) Stake Lessened by AMP Capital Investors Ltd

AMP Capital Investors Ltd decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 20.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 78,202 shares of the medical equipment provider’s stock after selling 20,644 shares during the period. AMP Capital Investors Ltd’s holdings in Hologic were worth $2,869,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Hologic by 4.2% in the second quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock valued at $1,340,850,000 after acquiring an additional 1,200,825 shares in the last quarter. Parnassus Investments CA bought a new stake in Hologic in the third quarter valued at $277,062,000. Capital World Investors bought a new stake in Hologic in the second quarter valued at $312,441,000. Victory Capital Management Inc. boosted its holdings in Hologic by 16.8% in the third quarter. Victory Capital Management Inc. now owns 5,856,778 shares of the medical equipment provider’s stock valued at $214,885,000 after acquiring an additional 844,426 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in Hologic by 2.5% in the second quarter. Northern Trust Corp now owns 3,277,739 shares of the medical equipment provider’s stock valued at $148,743,000 after acquiring an additional 79,697 shares in the last quarter. Hedge funds and other institutional investors own 98.08% of the company’s stock.

In other news, Director Elaine Ullian sold 9,282 shares of Hologic stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Karleen Marie Oberton sold 1,023 shares of Hologic stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,833 shares of company stock valued at $1,107,270. 0.79% of the stock is owned by insiders.

Hologic, Inc. (NASDAQ:HOLX) opened at $43.53 on Monday. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61. The stock has a market capitalization of $12,000.52, a PE ratio of 21.55, a PEG ratio of 2.10 and a beta of 0.95. Hologic, Inc. has a 52-week low of $35.76 and a 52-week high of $46.80.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.01. The firm had revenue of $802.90 million during the quarter, compared to analyst estimates of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. Hologic’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.52 EPS. research analysts expect that Hologic, Inc. will post 2.12 earnings per share for the current year.

A number of analysts have recently commented on HOLX shares. Zacks Investment Research cut shares of Hologic from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Stifel Nicolaus restated a “buy” rating and set a $45.00 target price (down previously from $48.00) on shares of Hologic in a report on Monday, October 9th. Goldman Sachs Group upgraded shares of Hologic from a “buy” rating to a “conviction-buy” rating and boosted their target price for the company from $45.00 to $50.00 in a report on Friday, December 8th. Needham & Company LLC restated a “buy” rating and set a $50.00 target price on shares of Hologic in a report on Friday, November 3rd. Finally, Jefferies Group restated a “buy” rating and set a $44.00 target price (down previously from $49.00) on shares of Hologic in a report on Tuesday, October 10th. One analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $47.86.

TRADEMARK VIOLATION WARNING: This news story was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://sportsperspectives.com/2017/12/18/hologic-inc-holx-stake-lessened-by-amp-capital-investors-ltd.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply